Czech investigators have disclosed that a Boeing 737 crew levelled the aircraft at a low height on approach to Marsa Matruh airport in Egypt, after descending on final approach with an incorrect ...
(RTTNews) - Vor Biopharma Inc. (VOR) announced the pricing of an underwritten public offering of 10 million shares of its common stock at a public offering price of $10.00 per share. The company ...
Please provide your email address to receive an email when new articles are posted on . A large cohort study showed high prevalence of bilateral diabetic macular edema at first visit. The intensity of ...
Shares of Vor Bio (Nasdaq: NASDAQ:VOR) rose after it reported that its partner, RemeGen (OTCPK:REGMF), met the main goal in a late-stage trial in China evaluating telitacicept for treating Sjögren’s ...
A psychologist argues that the sensation is not mysterious, but rather an emotion that scientists can detect. By Emma Goldberg There’s a type of awe that surrounds the Jewish High Holy Days that is ...
On Wednesday, Vor Bio Inc. (NASDAQ:VOR) announced that its collaborator, RemeGen Co., Ltd., achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in ...
Hosted on MSN
Trying a VOR Instrument Approach!
I love being a licensed private pilot. As you may have seen from other videos, I am starting my instrument rating training. I really believe that I will be a much safer pilot when I get my IFR or ...
Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.
(RTTNews) - Vor Bio (VOR) and RemeGen Co. announced entry into a license agreement granting Vor Bio global rights excluding China, Hong Kong, Macau and Taiwan to develop and commercialize telitacicept ...
Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions
Less than two months after Vor Bio telegraphed a strategic review, the former cell therapy biotech has made a surprise comeback with a potential $4 billion deal licensing a China-made autoimmune asset ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After announcing plans to wind ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results